Vir Biotechnology (VIR) Q2 2024 earnings summary

Executive summary

• Announced exclusive worldwide license agreement with Sanofi for three clinical-stage dual-masked T-cell engagers and the Pro-XTEN protease-cleavable masking platform, enhancing the clinical pipeline and value creation opportunities; agreement subject to HSR clearance.

• Strategic restructuring includes a 25% workforce reduction (~140 employees), closure of St. Louis and Portland R&D facilities, and phasing out of influenza, COVID-19, and T-cell-based viral vector programs to focus on hepatitis delta, hepatitis B, and masked TCEs.

• Pipeline now centers on hepatitis delta, hepatitis B, and the newly licensed T-cell engager portfolio, with multiple near-term clinical catalysts expected in the next 4–18 months.

• Appointed new Chief Medical Officer and two new independent directors to support strategic shift.

Financial highlights

• Q2 2024 total revenues were $3.1M, up from negative $13.8M in Q2 2023, driven by lower loss from sotrovimab sales and contract revenue.

• R&D expenses for Q2 2024 were $105.1M, down from $168.1M in Q2 2023, reflecting cost-saving initiatives and program wind-downs.

• SG&A expenses for Q2 2024 were $30.3M, down from $45.5M in Q2 2023, reflecting cost-saving initiatives.

• Net loss for Q2 2024 was $138.4M, improved from $194.8M in Q2 2023; net loss per share was $(1.02).

• Cash, cash equivalents, and investments totaled $1.43B as of June 30, 2024, a $78M decrease from Q1 2024.

Outlook and guidance

• 2024 full-year GAAP operating expenses now guided to $580M–$610M, a $70M reduction from prior guidance, with a 26% year-over-year decline at the midpoint (excluding non-cash and restructuring costs).

• Guidance excludes $100M upfront and $75M milestone payments related to the Sanofi agreement, which will be incorporated in Q3 2024 guidance.

• Anticipated cost savings of $50M annually from workforce restructuring and $50M through end of 2025 from phased-out programs; most savings to be reinvested in new Sanofi-licensed programs.

• Cash utilization in H2 2024 expected to be similar to H1 2024; existing cash and investments expected to fund operations for at least the next 12 months.